Chart — Maternal-Newborn
Diabetes in Pregnancy Comparison Chart
The dividing line is timing: gestational diabetes begins after organogenesis, so its risks are about growth; pre-existing diabetes is present during organogenesis, so its risks start with formation — and everything in management follows from that difference.
Educational use only. Targets, screening, and insulin management follow provider orders and current guidelines — this chart compares the conditions for learning. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
GDM vs Pre-Existing Diabetes
| Feature | Gestational Diabetes | Pre-Existing Type 1 / Type 2 |
|---|---|---|
| Onset / detection | Develops mid-pregnancy from placental insulin resistance; found by 24–28 week screening | Predates pregnancy; managed from the first prenatal visit (early A1c) |
| First-trimester risk | Minimal — glucose is typically normal during organogenesis | Congenital anomaly risk rises with periconception A1c — preconception control is the intervention |
| Management | Nutrition and activity first; insulin added when targets miss (most never need it) | Insulin from the start for type 1; type 2 commonly transitions to insulin; needs climb steeply through pregnancy |
| Hypoglycemia risk | Low unless on insulin | Significant — especially type 1 in the first trimester and with tightened targets |
| DKA risk | Rare | Real in type 1 — can occur at lower glucose levels in pregnancy and is a fetal emergency |
| Fetal/neonatal risks | Macrosomia, shoulder dystocia, neonatal hypoglycemia, polyhydramnios | All of those plus anomalies (timing of exposure), growth restriction with vascular disease, stillbirth risk — denser surveillance |
| Labor & delivery | Glucose checks per protocol; anticipate dystocia with macrosomia; newborn glucose monitoring | Often insulin/dextrose infusions with hourly glucose; same newborn vigilance, higher stakes |
| After delivery | Resistance resolves — most stop treatment; OGTT at 4–12 weeks; high lifetime type 2 risk | Insulin needs drop sharply (watch hypoglycemia); chronic management resumes and continues |
The Shared Endpoint
• Both pathways converge on the same newborn risk: hyperinsulinemic hypoglycemia after the cord is cut — early feeds and glucose checks for every infant of a diabetic mother
• Both demand tighter glucose targets than non-pregnant care
• Both make jitteriness, poor feeding, and lethargy in the newborn a glucose check, not an observation note
Related Resources
Standards & sources
Fact-checked Jun 20, 2026This page is written to align with American College of Obstetricians and Gynecologists (ACOG) · AWHONN · American Academy of Pediatrics (AAP) — newborn. It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →